drugset / Trial / NCT03919929
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Phase 2/3
Completed
60 enrolled
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Timeline
- Start
- 2019-05-03
- Primary completion
- 2023-10-03
- Completion
- 2023-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 3 mg | Oral |
| Subject | Semaglutide | Peptide | 7 mg | Oral |